Adam S. Grossman, who serves as President and Chief Executive Officer of ADMA Biologics, INC. (NASDAQ: ADMA), reported the sale of 21,000 shares of common stock on February 17, 2026. The shares were sold at $16.08 per share, producing total proceeds of $337,679, according to a Form 4 filed with the Securities and Exchange Commission.
The disposition occurred close to the company's quoted share price at the time of $15.95. InvestingPro data included with the filing lists the stock's price-to-earnings multiple at 18.95 and characterizes the company as exhibiting strong financial health.
The Form 4 also documents that Grossman exercised stock options in connection with the transactions. He exercised options to acquire 15,000 shares of ADMA Biologics common stock at an exercise price of $5.40 per share, for an aggregate exercise cost of $81,000.
Ownership details reported after the transactions show Grossman directly holds 2,284,379 shares of ADMA Biologics. He additionally retains indirect stakes via two entities: 1,143,426 shares through Areth, LLC, and 580,957 shares through Hariden, LLC.
The reported sales were executed under a previously established Rule 10b5-1 trading plan that Grossman put in place on November 14, 2025. The filing does not indicate any deviation from that plan.
InvestingPro information included with the filing places ADMA Biologics' market capitalization at approximately $3.8 billion. The company has reported profitability over the last twelve months with a diluted earnings per share figure of $0.86. Analyst price targets compiled by InvestingPro range from $17 to $30. ADMA Biologics' next scheduled earnings announcement is noted as March 19, 2026.
This report is based on the information contained in the SEC filing and the accompanying InvestingPro data cited in that filing.